Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Editor's Note
The SGLT-2 inhibitors continue to garner headlines and scientific publications as our knowledge of how they work and what they can do increases. Part of the reason all this is happening at a rapid pace is the multiple brands available on the class. This means that endpoint studies can be going on that we don’t even know about and meta evaluations of these many studies often mean we will find another benefit from the class. This month we have a set of interviews with Dr. Jim McDermott, Vice President of US Medical Affairs for Diabetes at AstraZeneca.
He shares some of his insights in an exclusive 6-part interview that our publisher, Steve Freed, put together at the recent ADA Scientific Sessions.
Dave Joffe
Editor-in-chief
Short-term efficacy and safety of SGLT2 inhibitors have been well established, but what happens with long-lasting use of these medications?
Meta-analysis explores safety and efficacy of sodium-glucose co-transporter 2 inhibitors in patients with type 1 diabetes.
Therapy offers beneficial weight loss in treatment of diabetes, but which agent in the class leads to the greatest body weight reduction?
Dr. Jim McDermott is Vice President of US Medical Affairs for Diabetes at AstraZeneca. He has been with AstraZeneca for more than two decades.